The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
-
Cancer and Blood Specialty Clinic, Los Alamitos, California, United States, 90720
Sharp Memorial Hospital, San Diego, California, United States, 92123
Private Practice - Dr. James R. Berenson, West Hollywood, California, United States, 90069
Local Institution - 0381, Aurora, Colorado, United States, 80045
Local Institution - 0380, Farmington, Connecticut, United States, 06030
Advanced Research, Coral Springs, Florida, United States, 33321
Local Institution - 0403, Fort Myers, Florida, United States, 33901
Local Institution - 0401, Saint Petersburg, Florida, United States, 33705
Local Institution - 0402, West Palm Beach, Florida, United States, 33401
University Cancer Blood Ctr, Athens, Georgia, United States, 30607
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Celgene,
Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb
2033-11-30